1. Current treatment options for HER2-positive breast cancer patients with brain metastases.
- Author
-
Galanti D, Inno A, La Vecchia M, Borsellino N, Incorvaia L, Russo A, and Gori S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Oxazoles, Pyridines, Quality of Life, Quinazolines, Receptor, ErbB-2 genetics, Trastuzumab therapeutic use, Brain Neoplasms drug therapy, Breast Neoplasms drug therapy
- Abstract
Brain metastases (BMs) are frequently associated with HER2+ breast cancer (BC). Their management is based on a multi-modal strategy including both local treatment and systemic therapy. Despite therapeutic advance, BMs still have an adverse impact on survival and quality of life and the development of effective systemic therapy to prevent and treat BMs from HER2 + BC represents an unmet clinical need. Trastuzumab-based therapy has long been the mainstay of systemic therapy and over the last two decades other HER2-targeted agents including lapatinib, pertuzumab and trastuzumab emtansine, have been introduced in the clinical practice. More recently, novel agents such as neratinib, tucatinib and trastuzumab deruxtecan have been developed, with interesting activity against BMs. Further research is needed to better elucidate the best sequence of these agents and their combination with local treatment., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF